Amrita Jain

LongeVC is a venture capital firm, founded in 2020 by Garri Zmudze, Ilya Suharenko, Sergey Jakimov. The firm is headquartered in Lugano, Switzerland.

Fusix Biotech GmbH is a private company located in Germany that aims to deliver breakthrough cancer immunotherapies utilizing a unique "fusogenic" mechanism of action to directly kill tumor cells, heat up the tumor microenvironment, and mediate systemic immune effects to target tumor cells throughout the body. The German company is still part of the Klinikum rechts der Isar of the Technical University Munich and is currently planning to spin-out in 2022. The Fusix technology offers a unique mechanism of action that will revolutionize immune oncology in solid cancers by converting the tumor microenvironment from an immune suppressed “cold” tumor into an immune-sensitized “hot” tumor infiltrated with immunotherapeutics.

Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999.